ATYR Pharma(ATYR.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
ATYR Pharma
ATYR.US
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd.
1.880 T
ATYR.USMarket value -Rank by Market Cap -/-

Financial Score

20/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking287/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-103.22%E
    • Profit Margin-39537.89%E
    • Gross Margin-11547.37%E
  • Growth ScoreD
    • Revenue YoY-19.15%E
    • Net Profit YoY-17.72%D
    • Total Assets YoY16.41%A
    • Net Assets YoY22.88%A
  • Cash ScoreD
    • Cash Flow Margin-0.25%D
    • OCF YoY-19.15%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio24.95%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    6 Interesting Tax Selling Stocks For A Possible January Bounce

    The article discusses a contrarian investment strategy of buying stocks that have fallen sharply by year-end due to tax-loss selling. This approach aims to exploit temporary price distortions, with potential rebounds in January as selling pressure eases. The strategy focuses on stocks down over 75%, selling below book value and cash per share, with market caps above $65 million. Six stocks identified as potential candidates for a January bounce include Atyr Pharma, Korro Bio, New Fortress Energy, Pliant Therapeutics, Vivid Seats, and Teads Holding.

    Talkmarkets·
    US
    NFE
    +1.43%
    US
    SEAT
    +5.84%
    US
    KRRO
    -0.23%
    Talkmarkets·
    US
    NFE
    +1.43%
    US
    SEAT
    +5.84%
    US
    KRRO
    -0.23%

    02:14 ET ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

    The Schall Law Firm announces a class action lawsuit against aTyr Pharma, Inc. for securities fraud, alleging false and misleading statements about the Phase 3 trial of Efzofitimod. Investors who purchased securities between January 16, 2025, and September 12, 2025, are encouraged to join the lawsuit before December 8, 2025, to recover losses.

    prnewswire·
    prnewswire·

    10:56 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

    Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. for allegedly making false and misleading statements about the efficacy of its drug, Efzofitimod. Investors who suffered losses are encouraged to contact the firm. The deadline to seek the role of lead plaintiff in the class action is December 8, 2025. The lawsuit claims that misleading information led to artificially inflated stock prices, which dropped significantly after study results were released.

    prnewswire·
    US
    ATYR
    +0.30%
    prnewswire·
    US
    ATYR
    +0.30%

    aTyr Pharma Faces Investor Class Action After Drug Trial Failure

    aTyr Pharma Inc. is facing a class action lawsuit from investors who incurred losses between November 7, 2024, and September 12, 2025. The lawsuit claims the company made false statements about its drug candidate, Efzofitimod. The issue was revealed on September 15, 2025, when the drug failed its primary endpoint, causing the stock price to plummet by 83.2%. The legal action aims to recover losses for shareholders.

    Reuters·
    US
    ATYR
    +0.30%
    Reuters·
    US
    ATYR
    +0.30%

    aTyr Pharma Reveals EFZO-FIT Study Missed Primary Endpoint in Investor Call

    aTyr Pharma announced that the EFZO-FIT study missed its primary endpoint, leading to a significant stock price drop from $6.03 to $1.02. The company plans to engage with the FDA to determine next steps.

    Reuters·
    US
    ATYR
    +0.30%
    Reuters·
    US
    ATYR
    +0.30%
    © 2026 Longbridge｜Disclaimer